3 Stocks Every Investor Should Own

NYSE: NVO | Novo Nordisk A/S ADR News, Ratings, and Charts

NVO – The Fed’s commitment to tame the sticky inflation is feared to trigger an economic slowdown in the near term. Amid such concerns, investors’ anxiety has been rising. Against this backdrop, quality stocks Novo Nordisk (NVO), Altria Group (MO), and Cardinal Health (CAH) might be owned by every trader at least once. Read on to find more….

The odds of a Fed-induced recession have been soaring amid sky-high inflation, resilient spending, and robust job data. Investors’ sentiments are simultaneously being hampered. Given that the volatilities could persist in the upcoming months, let us probe into stocks such as Novo Nordisk A/S (NVO), Altria Group, Inc. (MO), and Cardinal Health, Inc. (CAH).

The Fed’s efforts to tame the stubbornly high inflation will likely continue in the upcoming months of 2023 on the backs of stronger-than-anticipated job growth and resilient consumer spending despite high prices. A bout of anxiety has set in among investors post the Fed’s hawkish comments related to rate hikes.

Moreover, since inflation is still far above the target range of 2%, the Fed’s minutes signaled higher interest rate hikes in the near term. The CEO of Bank of America Corporation (BAC), Brian Moynihan, predicts the figure won’t begin to dip for at least another 12 months.

He explained, “They’re going to have to hold it there for a long time, because frankly, the labor market is still very tight, despite what you hear about layoffs, and financial conditions are strong, so companies have access to capital, albeit at higher costs.”

Furthermore, fearing such rate hikes could cause an economic downturn, he predicts the economy will contract by 0.5% and 1% each quarter, with a slight recession setting in the third quarter of 2023.

Furthermore, economist Nouriel Roubini has warned that the era of ultra-low inflation is over. He also believes that since there exist debts in the system, interest rate hikes further could lead to a real hard landing, leading to severe debts.

Amid uncertainties looming, fundamentally strong stocks NVO, MO, and CAH might be solid portfolio additions now.

Novo Nordisk A/S (NVO)

Headquartered in Bagsvaerd, Denmark, NVO is a global healthcare company engaged in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company operates through two segments: Diabetes and Obesity care; and Biopharm.

On 1 February 2023, NVO initiated a share repurchase program as a part of the overall share repurchase program of up to Kr 28 billion ($3.97 billion) to be executed during a 12-month period. Under this program, NVO intends to repurchase B shares for an amount up to Kr 5.60 billion ($793.26 million) in the period between 1 February 2023 and 2 May 2023.

NVO’s forward non-GAAP PEG multiple of 1.33 is 32.6% lower than the industry average of 1.98. Its trailing-12-month EBITDA margin of 45.73% is significantly higher than the 3.39% industry average.

NVO’s net sales for the fiscal year that ended December 31, 2022, increased 25.7% year-over-year to Kr176.95 billion ($25.07 billion), while its operating profit increased 27.6% year-over-year to Kr74.81 billion ($10.60 billion). The company’s net profit during the period was Kr55.53 billion ($7.87 billion) and Kr24.44 per share, up 16.3% and 17.8% year-over-year, respectively.

Analysts expect NVO’s EPS and revenue for the fiscal quarter ending March 2023 to increase 21.6% and 15% year-over-year to $1.07 and $6.90 billion, respectively. It surpassed revenue estimates in three out of the trailing four quarters.

The stock has gained 1.3% over the past month and 33.84% over the past six months to close the last trading session at $141.46.

NVO’s POWR Ratings reflect this promising outlook. The company has an overall A rating, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

It has an A grade for Quality and a B for Value, Stability, and Sentiment. NVO tops the list of 169 stocks in the Medical – Pharmaceuticals industry. 

Click here for additional ratings for NVO’s Growth and Momentum.

Altria Group, Inc. (MO)

MO manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes, cigars, pipe tobacco, moist smokeless tobacco products, and oral nicotine pouches.

On March 6, MO announced that it had entered into a definitive agreement to acquire NJOY Holdings, Inc. for approximately $2.75 billion in cash payable at closing. The transaction terms include an additional $500 million in cash payments, contingent upon regulatory outcomes concerning certain NJOY products.

As a result of this transaction, MO’s enhanced smoke-free portfolio is expected to include full global ownership of products and technologies across the three largest smoke-free categories and a joint venture with JT Group for the commercialization of heated tobacco stick products.

On March 1, 2023, MO’s board of directors declared a quarterly dividend of $0.94 per share, payable to shareholders on April 28. 2023. This reflects its cash generation abilities.

The company paid dividends worth $1.70 billion in the fourth quarter and $6.60 billion for the full year.

In the fourth quarter, MO repurchased 8.3 million shares at an average price of $45.09, for a total cost of $374 million. Its board of directors authorized a new $1 billion share repurchase program, which is expected to complete by December 31, 2023.

In terms of its forward EV/EBIT, MO is trading at 8.55x, 42.9% lower than the industry average of 14.96x, while its forward non-GAAP P/E multiple of 9.21 is 49.1% lower than the industry average of 18.07.

MO’s revenue for the fiscal fourth quarter that ended December 31, 2022, stood at $6.11 billion. Its operating revenue increased 3.1% year-over-year to $2.82 billion. Adjusted net earnings attributable to MO rose 6% from the prior-year quarter to $2.11 billion. In addition, its adjusted EPS came in at $1.18, representing an increase of 8.3% year-over-year.

Analysts expect MO’s EPS and revenue for the first quarter ending March 31, 2023, to increase 5.9% and 1.9% year-over-year to $1.19 and $4.91 billion, respectively. It topped the consensus EPS estimates in three of the trailing four quarters.

Over the past six months, the stock has gained 3.7% to close the last trading session at $46.80. It increased marginally intraday.

MO’s promising prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to Buy in our proprietary rating system.

The stock has an A grade for Quality. Within the A-rated Tobacco industry, it is ranked #5 out of nine stocks.

To see the additional POWR Ratings of MO for Growth, Value, Momentum, Stability, and Sentiment, click here.

Cardinal Health, Inc. (CAH)

CAH is a provider of integrated healthcare services and solutions. It offers customized solutions for healthcare organizations like hospitals, pharmacies, clinical laboratories, and patients receiving care at home. The company operates through two segments, Pharmaceutical and Medical.

On March 6, 2023, CAH announced its collaboration with Signify Health (SGFY) to offer in-home clinical and medication management services through its outcomes business. This collaboration should help reduce costs and eliminate gaps in care for more than 2.3 million members nationwide to support their treatment journey from prescription to the pharmacy to home.

On February 10, CAH announced a quarterly dividend of $0.4957 per share from the company’s capital surplus, payable to shareholders on April 15, 2023. This reflects the company’s cash generation abilities.

In terms of its forward EV/Sales, CAH is trading at 0.10x, 97.4% lower than the industry average of 3.83x, while its forward non-GAAP P/E multiple of 13.39 is 31.3% lower than the industry average of 19.50.

For the second quarter of the fiscal year 2023, which ended December 31, 2022, CAH’s revenues increased 13.2% year-over-year to $51.47 billion. Its gross margin was $1.66 billion, indicating a 2.9% increase year-over-year.

Revenue for the pharmaceutical segment rose 15.2% year-over-year to $47.67 billion, while profit for the same segment increased 8.9% from the year-ago value to $464 million. Non-GAAP EPS for the same quarter stood at $1.32, representing an increase of 3.9% year-over-year.

Analysts expect CAH’s EPS for the fiscal third quarter ending March 2023 to increase 1.9% year-over-year to $1.48. Moreover, the company’s revenue for the same quarter is expected to grow 10.3% from the prior-year period to $49.45 billion. The company surpassed revenue estimates in all the trailing four quarters, which is impressive.

The stock has gained 38.6% over the past year to close the last trading session at $72.65. Moreover, it has gained 2.9% over the past six months.

CAH’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.

The stock has a B grade for Growth and Value. Within the Medical – Services industry, it ranks #2 out of 77 stocks.

Beyond what has been stated above, we have also given CAH’s ratings for Momentum, Stability, Sentiment, and Quality. Get all CAH ratings here.

What To Do Next?

Get your hands on this special report:

3 Stocks To DOUBLE This Year

What gives these stocks the right stuff to become big winners, even in this brutal stock market?

First, because they are all low-priced companies with the most upside potential in today’s volatile markets.

But even more important is that they are all top Buy rated stocks according to our coveted POWR Ratings system, and they excel in key areas of growth, sentiment and momentum.

Click below now to see these 3 exciting stocks that could double or more in the year ahead.

3 Stocks To DOUBLE This Year


NVO shares were trading at $143.53 per share on Thursday morning, up $2.07 (+1.46%). Year-to-date, NVO has gained 6.05%, versus a 4.51% rise in the benchmark S&P 500 index during the same period.


About the Author: Sristi Suman Jayaswal


The stock market dynamics sparked Sristi's interest during her school days, which led her to become a financial journalist. Investing in undervalued stocks with solid long-term growth prospects is her preferred strategy. Having earned a master's degree in Accounting and Finance, Sristi hopes to deepen her investment research experience and better guide investors. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
NVOGet RatingGet RatingGet Rating
MOGet RatingGet RatingGet Rating
CAHGet RatingGet RatingGet Rating
BACGet RatingGet RatingGet Rating
SGFYGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Is This REALLY a Bull Market?

The S&P 500 (SPY) keeps making record highs...but does that mean that market conditions are truly bullish? 44 year investment veteran shines a light on how hollow recent gains are as they are only accruing to a handful of stocks with most investors searching high and low for stock market gains. Read on for more...

Unveiling Adobe (ADBE) Q2 Earnings: What Lies Ahead for Investors?

Software giant Adobe Inc. (ADBE) has released its second-quarter earnings, revealing double-digit growth in both revenue and profits. Yet, concerns arise around the complexities of navigating growth in the face of advancing AI technologies. Let’s analyze ADBE’s recent performance and assess key fundamentals to uncover what lies ahead for investors…

3 AI Stocks to Invest in for the Next Technological Revolution

The AI market is experiencing a significant growth trajectory, driven by widespread application across various industries. Hence, it could be wise to invest in top AI stocks, Alphabet (GOOGL), Meta Platforms (META), and Alibaba Group Holding (BABA) for the next technological revolution. Read more...

Analyzing Broadcom’s (AVGO) Q2 Earnings: Worth Investing?

Driven by a surge in demand for its AI products, Broadcom (AVGO) reported robust earnings in its latest quarterly results, exceeding expectations on both top and bottom lines. However, is the stock’s recent announcement of a 10-for-1 stock split worth investing in? Keep reading to find out…

Bullish or Bearish Stock Set Up?

The S&P 500 (SPY) record highs sounds pretty darn bullish on the surface. Yet as we dig below the surface there are some curious signals that point more Risk Off. This is especially true as we come into the next Fed meeting after a round of data that points to inflation still being too high...only further delaying the first rate cut. What does this all mean for stocks from here? Steve Reitmeister offers his latest views on the market outlook along with a preview of his top picks to stay on step ahead of the market. Read on for more...

Read More Stories

More Novo Nordisk A/S ADR (NVO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NVO News